Li LX, Cappuzzo F, Matos I, Socinski MA, et al. Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials. Oncologist 2023 Mar 11:oyad043. doi: 10.1093.
PMID: 36905578